The total number of coronary vaccines in China has reached more than 700 million doses. Zeng Yixin, deputy director of the National Health Commission, believes that it is expected that China will complete at least 70%of the target group by the end of this year.
Zeng Yixin accepted an interview with Xinhua News Agency yesterday (6th) that the total number of domestic vaccination is far ahead of the world, but the proportion of per 100 people is not ahead.Under such circumstances, Chinese officials are based on the domestic and foreign epidemic situation, coordinate the domestic and international needs, and reasonably allocate vaccine supply.
Zeng Yixin pointed out that the Chinese vaccine use population has covered over 18 years old, and the maximum of the vaccination is more than 100 years old. Experts have now demonstrated the safety and effectiveness of the vaccine of the vaccine 3 to 17 years old.After approval, it will also be used in this population as needed.
China has previously approved the emergency use age range of the Koxing biological coronary vaccine to over 3 years old, becoming the first major country to increase the age range of the crown vaccination to a minimum of 3 years.
Zeng Yixin said that in China in more than 700 million doses in China, the incidence of adverse reaction reports was 11.86 times per 100,000 doses, of which 83%were generally reactions, and abnormal reactions accounted for 17%.It is also lower than the average reporting level of various types of vaccines in China in 2019.
Zeng Yixin has also announced that there are 21 crown disease vaccines in China entering the clinical trial stage. Currently, four vaccines have been approved to be available in China. Three vaccines have been approved in China for emergency use.The phase III clinical trial was approved, and an MRNA (messenger ribonucleic acid) vaccine obtained ethical approval abroad, achieving a comprehensive coverage of overseas clinical trials, reorganized protein vaccines, adenovirus vaccine vaccines, and nucleic acid vaccine technology routes.
Zhong Nanshan, an expert on respiratory diseases in China last month, predicted that the coverage of China's crown vaccine can reach 80%by the end of this year,
